Biotest Pharmaceuticals names new chief executive

Jordan Siegel is promoted from chief financial officer

Jordan Siegel will become chief executive of Biotest Pharmaceuticals Corporation (BPC), a wholly owned subsidiary of Biotest AG of Dreieich, Germany, on 1 May.

BPC’s interim chief executive, Georg Floss, will return to Germany on 30 April to assume the role of global head of operations at Biotest AG.

Siegel has been BPC’s senior vice president, finance and chief financial officer since its inception in 2007.

BPC researches, develops and manufactures biotherapeutic products for immunology and haematology. The firm is a leader in the collection of source plasma and is currently involved in the development of plasma protein products in the field of Primary Immune Deficiency (PID) and various hyperimmune (IG) products. It owns and manages 12 plasmapherisis centres across the US and a manufacturing facility in Boca Raton, Florida.

You may also like

Design & Build
Agilent expands Boulder facility with dedicated enzymatic ligation laboratory for oligonucleotide therapeutics

Agilent expands Boulder facility with dedicated enzymatic ligation laboratory for oligonucleotide therapeutics

The new space complements established solid-phase synthesis operations, giving Agilent's Advanced Therapeutics Division a dedicated environment to develop solvent-free enzymatic manufacturing approaches as oligonucleotide pipeline demand grows
Finance
Piramal Pharma receives Ontario investment for API site

Piramal Pharma receives Ontario investment for API site

Piramal Pharma Solutions (PPS) is to invest more than $5.3m in upgrading its drug substance manufacturing site in Aurora, Canada, supported by a $1.75m investment from the Ontario government
Manufacturing
Piramal Pharma Solutions and NP2 to complete cyclophosphamide development phase next month

Piramal Pharma Solutions and NP2 to complete cyclophosphamide development phase next month

Piramal Pharma Solutions (“PPS”), a leading global Contract Development and Manufacturing Organisation (CDMO) and part of Piramal Pharma Ltd. (“PPL”) (NSE: PPLPHARMA | BSE: 543635), and its partner NP2, a nonprofit generic drug manufacturer, today announced their plans to finish the drug development phase of the generic cancer drug cyclophosphamide in October
Research & Development
Quotient Sciences and Acesion Pharma collaborate on AI-enhanced formulation development

Quotient Sciences and Acesion Pharma collaborate on AI-enhanced formulation development

New AI-enhanced solution helps identify promising drug formulations, compressing early clinical decision-making for new treatments
Pharmaceutical
Biosynth expands complex chemistry portfolio for biologics and vaccines

Biosynth expands complex chemistry portfolio for biologics and vaccines

The expansion includes new fluorinated sugars and GMP-grade Poly(I:C), supporting glycoengineering, bioproduction, vaccine and immunotherapy development
Media
FUJIFILM Biotechnologies lands three CPHI Pharma Award nominations for continuous manufacturing and precision purification

FUJIFILM Biotechnologies lands three CPHI Pharma Award nominations for continuous manufacturing and precision purification

The CDMO's MaruX platform, ShunzymeX purification technology and COO Maja Pedersen are all shortlisted ahead of its CPHI Milan appearance at booth 8A2, where senior leadership will present on Europe's biomanufacturing strategy
Pharmaceutical
AI in quality: Why human judgment still matters in an automated world

AI in quality: Why human judgment still matters in an automated world

Explore the rise of AI in pharmaceutical quality and the risks of over-reliance, examining why experience, instinct and critical thinking remain essential to sound professional judgement
Subscribe now